Premium
Effect of piroxicam administration on outcome of frozen–thawed embryo transfer: A randomized, double‐blinded, placebo‐controlled trial
Author(s) -
Zarei Afsoon,
Homayoon Nahid,
Hessami Kamran,
Hashemi Atefe,
Davoodi Sara,
Razavi Behnaz,
Ghasempour Leila,
Alamdarloo Shaghayegh Moradi
Publication year - 2021
Publication title -
journal of obstetrics and gynaecology research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.597
H-Index - 50
eISSN - 1447-0756
pISSN - 1341-8076
DOI - 10.1111/jog.14521
Subject(s) - medicine , placebo , piroxicam , embryo transfer , pregnancy , randomized controlled trial , pregnancy rate , double blinded , clinical trial , obstetrics , gynecology , surgery , alternative medicine , pathology , biology , genetics
Aim This study aimed to evaluate the effect of piroxicam adjuvant therapy on the clinical and biochemical pregnancy rate in patients undergoing in vitro fertilization (IVF) and frozen–thawed embryo transfer (ET) cycles. Methods In a randomized, double‐blinded, placebo‐controlled clinical trial, 178 patients eligible for IVF‐ET received either single dose of piroxicam 1–2 h before frozen–thawed ET or a placebo at the same time. Study participants were then followed and compared regarding the primary outcome of the study, which was biochemical (positive β‐human chorionic gonadotrophin test) and clinical pregnancy (detected fetal heart beat in ultrasound) rate. Results The results of this study indicated that there is no significant association between the piroxicam administration before frozen–thawed ET and the clinical or biochemical pregnancy rate ( P = 0.208 and P = 0.699, respectively). Conclusion The findings of the current study suggest that piroxicam administration before ET has no beneficial effects on pregnancy rate among women undergoing IVF and frozen–thawed ET. However, further studies with larger sample sizes and longer follow‐ups are recommended.